Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
$11.27
-4.3%
$11.57
$10.47
$29.12
$168.94M0.6476,030 shs76,049 shs
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$2.72
-4.6%
$2.35
$1.11
$13.91
$55.54M1.57391,901 shs330,191 shs
Cerus Corporation stock logo
CERS
Cerus
$1.45
-6.5%
$1.36
$1.12
$2.54
$296.30M1.561.32 million shs733,330 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$3.10
+1.6%
$2.84
$2.36
$4.92
$228.14M0.45746,030 shs682,037 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
+5.75%+4.57%+1.99%-13.64%-55.04%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
+6.27%+20.75%-0.38%+120.52%-76.28%
Cerus Corporation stock logo
CERS
Cerus
+4.03%+3.33%+7.64%+12.32%-17.11%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
+0.66%-0.97%+2.01%+4.10%-27.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
4.315 of 5 stars
3.83.00.03.72.71.70.6
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
1.5589 of 5 stars
3.51.00.00.00.61.70.6
Cerus Corporation stock logo
CERS
Cerus
2.5726 of 5 stars
3.52.00.00.02.91.70.6
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.5548 of 5 stars
1.03.00.04.22.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
3.50
Strong Buy$20.0077.46% Upside
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
3.00
Buy$18.00561.76% Upside
Cerus Corporation stock logo
CERS
Cerus
3.00
Buy$3.50141.38% Upside
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.00
Hold$3.00-3.23% Downside

Current Analyst Ratings Breakdown

Latest ANIK, ANVS, CERS, and OSUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $12.00
5/19/2025
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingIn-Line ➝ In-Line$3.00 ➝ $3.00
5/15/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $17.00
5/12/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.00
4/17/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/16/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
$119.91M1.35$0.09 per share123.50$10.51 per share1.07
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.67 per shareN/A
Cerus Corporation stock logo
CERS
Cerus
$180.27M1.54N/AN/A$0.31 per share4.68
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$185.83M1.25$0.04 per share78.56$5.50 per share0.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
-$56.38M-$3.88N/AN/AN/A-41.28%-7.22%-5.64%8/6/2025 (Estimated)
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)
Cerus Corporation stock logo
CERS
Cerus
-$20.92M-$0.10N/AN/AN/A-10.23%-34.81%-9.68%7/30/2025 (Estimated)
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-$19.50M-$0.42N/AN/AN/A-19.77%-5.86%-5.20%8/5/2025 (Estimated)

Latest ANIK, ANVS, CERS, and OSUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-$0.15N/AN/AN/A$30.52 millionN/A
5/13/2025Q1 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.47-$0.32+$0.15-$0.32N/AN/A
5/1/2025Q1 2025
Cerus Corporation stock logo
CERS
Cerus
-$0.05-$0.04+$0.01-$0.04$47.44 million$43.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
Cerus Corporation stock logo
CERS
Cerus
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.73
4.53
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
10.68
10.68
Cerus Corporation stock logo
CERS
Cerus
1.15
2.32
1.63
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
12.34
10.94

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
91.53%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
Cerus Corporation stock logo
CERS
Cerus
78.37%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%

Insider Ownership

CompanyInsider Ownership
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
9.64%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
20.80%
Cerus Corporation stock logo
CERS
Cerus
5.60%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
30014.34 million12.96 millionOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
319.49 million15.43 millionOptionable
Cerus Corporation stock logo
CERS
Cerus
290191.16 million180.46 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
84074.80 million71.88 millionOptionable

Recent News About These Companies

OraSure launches new blood collection device
OSUR - OraSure Technologies Inc Financials - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anika Therapeutics stock logo

Anika Therapeutics NASDAQ:ANIK

$11.27 -0.51 (-4.33%)
Closing price 04:00 PM Eastern
Extended Trading
$11.30 +0.04 (+0.31%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$2.72 -0.13 (-4.56%)
Closing price 03:59 PM Eastern
Extended Trading
$2.73 +0.01 (+0.37%)
As of 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Cerus stock logo

Cerus NASDAQ:CERS

$1.45 -0.10 (-6.45%)
Closing price 04:00 PM Eastern
Extended Trading
$1.45 0.00 (0.00%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

OraSure Technologies stock logo

OraSure Technologies NASDAQ:OSUR

$3.10 +0.05 (+1.64%)
Closing price 04:00 PM Eastern
Extended Trading
$3.04 -0.06 (-1.77%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.